List view / Grid view
Antibody-drug conjugates (ADC’s) are targeted cancer therapeutics that deliver a cytotoxic agent, the payload, to the tumour.
A group of researchers is showing how artificial intelligence approaches can help identify cause-effect relationships within data...
A new study suggests breast cancer patients taking palbociclib/letrozole combination therapy should avoid foods rich in xenoestrogens...
A study has shown that Adipocytes can absorb and metabolise the chemotherapeutic agent daunorubicin, reducing its ability to kill cancer cells.
Scientists have made progress in the development of products that improve mitochondrial function...
22 March 2017 | By Niamh Marriott, Junior Editor
The study intended to compare the plasma concentrations of sub-lingual apomorphine spray against the currently approved formulation...
4 March 2016 | By Victoria White
BAX 826 is a next-generation rFVIII treatment based on the full length Advate that uses proprietary polysialic acid technology to extend its circulating half-life...
4 March 2016 | By Victoria White
Sanofi Genzyme says the safety and efficacy data from the NEO1 study support further development of neoGAA...
3 September 2012 | By Vikash Sinha, Clinical Pharmacology Leader, Janssen Research and Development
One of the important goals in preclinical and early clinical drug development is to reduce attrition rates and to improve our ability to pick winners and drop potential loser drug candidates. By being able to efficiently translate preclinical data and observations into possible clinical outcomes, one can make the drug…
10 July 2012 | By Dr. Dermot McGinnity, Innovative Medicines, AstraZeneca R&D
Drug Metabolism and Pharmacokinetics (DMPK) is a scientific discipline once primarily associated with safety evaluation in drug development that has, in the last two decades, become a core discipline within drug discovery, development and even post-marketing. Approximately 20 years ago, sub-optimal DMPK properties were recognised as a contributor to the…
